Sacha Gnjatic

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
    Mitsutoshi Matsuo
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:14467-72. 2004
  2. doi Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays
    Sacha Gnjatic
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol Methods 341:50-8. 2009
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  4. pmc Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8862-7. 2003
  5. pmc CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11813-8. 2002
  6. ncbi Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:1191-6. 2003
  7. pmc Seromic profiling of ovarian and pancreatic cancer
    Sacha Gnjatic
    Ludwig Institute for Cancer Research Ltd, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:5088-93. 2010
  8. ncbi NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 127:381-93. 2010
  9. ncbi Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, and Department of Human Immunogenetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 172:3289-96. 2004
  10. ncbi Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 32, New York, NY 10021, USA
    J Immunol Methods 278:57-66. 2003

Detail Information

Publications79

  1. pmc IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
    Mitsutoshi Matsuo
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:14467-72. 2004
    ..This model of conditional cross-presentation establishes an original level of action for IFN-gamma as an effective immune modulator and supports the use of IFN-gamma in protein vaccination strategies targeting LCs...
  2. doi Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays
    Sacha Gnjatic
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol Methods 341:50-8. 2009
    ....
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  4. pmc Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8862-7. 2003
    ....
  5. pmc CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11813-8. 2002
    ....
  6. ncbi Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:1191-6. 2003
    ..e., HLA eligibility criteria and knowledge of epitope, while allowing for facilitated immunogenicity in the presence of helper epitopes...
  7. pmc Seromic profiling of ovarian and pancreatic cancer
    Sacha Gnjatic
    Ludwig Institute for Cancer Research Ltd, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:5088-93. 2010
    ..Serological analysis of arrays displaying the complete human proteome (seromics) represents a new era in cancer immunology, opening the way to defining the repertoire of the humoral immune response to cancer...
  8. ncbi NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 127:381-93. 2010
    ..Importantly, NY-CO-58/KIF2C was able to induce spontaneous CD4(+) T cell responses of the Th1-type, which were tightly controlled by peripheral T regulatory cells...
  9. ncbi Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, and Department of Human Immunogenetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 172:3289-96. 2004
    ..This development provides the framework for further evaluating integrated immune responses in vaccine settings and for optimizing these responses for clinical benefit...
  10. ncbi Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 32, New York, NY 10021, USA
    J Immunol Methods 278:57-66. 2003
    ..This approach makes it possible to monitor CD4+ T cells in large series of patients, regardless of HLA haplotype, against the full peptide repertoire of a given antigen...
  11. doi Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 183:4800-8. 2009
    ..It appeared that MAGE-A3 protein vaccination in the presence of adjuvant selectively expanded high avidity CD4+ T cells, whereas high avidity T cells disappeared after multiple vaccinations with MAGE-A3 protein alone...
  12. ncbi NY-ESO-1: review of an immunogenic tumor antigen
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Adv Cancer Res 95:1-30. 2006
    ..An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here...
  13. ncbi Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 188:3851-8. 2012
    ..Furthermore, targeted activation of tumor-recognizing CD4(+) T cells by vaccination or adoptive transfer could be a suitable strategy for enhancing the efficacy of tumor immunotherapy...
  14. pmc In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, and Section of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut 06536, USA
    J Clin Invest 116:1946-54. 2006
    ..We propose that antigen delivery through the S. typhimurium type III secretion system is a promising novel strategy for cancer vaccine development...
  15. pmc PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses
    Wilson A Silva
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 7:18. 2007
    ..We found by ELISA that PLAC1 is immunogenic in a subset of cancer patients and healthy women. Its physical and expression characteristics render it a potential target for both active and passive cancer immunotherapeutic strategies...
  16. ncbi Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Immunol 176:6340-6. 2006
    ..We propose that vaccination with NY-ESO-1(157-170) peptide recruits low-avidity T cells with low sensitivity to Tregs and fails to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors...
  17. ncbi Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
    Ali O Gure
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8055-62. 2005
    ..We asked whether cancer-testis gene expression occurred coordinately, and whether it correlated with variables of disease and clinical outcome of non-small cell lung cancer (NSCLC)...
  18. ncbi Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 111:1404-12. 2008
    ..We propose that S typhimurium-NY-ESO-1 induces antigen-specific T-cell responses that are resistant to suppression by CD4(+)CD25(+) Treg cells...
  19. doi Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6497-508. 2012
    ....
  20. ncbi CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 32 Rm K 817, New York, NY 10021, USA
    Blood 106:1008-11. 2005
    ..Memory populations were less sensitive than naive populations to CD4+CD25+ regulatory T cells. We propose that CD4+CD25+ regulatory T cells are involved in the generation and regulation of NY-ESO-1-specific antitumor immunity...
  21. ncbi Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Clin Cancer Res 12:398-404. 2006
    ..The aims of this study were to determine the expression and immunogenicity of these antigens in patients with epithelial ovarian cancer (EOC)...
  22. doi NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 15:2130-9. 2009
    ..Here, we report for the first time clinical and immune responses generated by the NY-ESO-1 DNA vaccine administered by particle-mediated epidermal delivery to cancer patients...
  23. pmc Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
    Yasuhiro Nagata
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:10629-34. 2002
    ..These results indicate that monocyte-derived DCs will be easier to load by using protein antigen in vitro than CD34-derived DCs, and that the latter population exhibits a restricted ability to crosspresent soluble exogenous antigens...
  24. pmc Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors
    Takemasa Tsuji
    Ludwig Institute for Cancer Research Ltd, New York Branch at Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e23651. 2011
    ....
  25. pmc Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
    Valerie Dutoit
    Ludwig Institute Clinical Trial Center, New York Branch at Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 110:1813-22. 2002
    ....
  26. ncbi Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  27. pmc Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:16723-8. 2011
    ....
  28. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
  29. pmc Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients
    Nikoletta Lendvai
    New York University Cancer Institute, New York University School of Medicine, New York, NY, USA
    Cancer Immun 10:4. 2010
    ..These data demonstrate that CTAgs, particularly CT7, are immunogenic in MM patients and merit further exploration as targets of immunological therapy in MM...
  30. ncbi Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  31. pmc MAGE-A3 is highly expressed in a subset of colorectal cancer patients
    H M C Shantha Kumara
    Division of Colon and Rectal Surgery, Department of Surgery, St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    Cancer Immun 12:16. 2012
    ..1%. Sero-reactivity specific for MAGE-A genes and PLAC1 was noted in 2.4% and 2.6% of patients, respectively. MAGE-A3 and PLAC1 may hold promise as vaccine targets for CRC. Further study is warranted...
  32. pmc Immunologic correlates of the abscopal effect in a patient with melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 366:925-31. 2012
    ..Funded by the National Institutes of Health and others.)...
  33. pmc Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
    Sylvia Adams
    Department of Medicine, Division of Medical Oncology, New York University Cancer Institute, School of Medicine, New York, NY 10016, USA
    J Immunol 181:776-84. 2008
    ..Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity...
  34. pmc Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas
    Yao Tseng Chen
    Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:3093-8. 2010
    ....
  35. pmc Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors
    Elsa F Velazquez
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Cancer Immun 7:11. 2007
    ..Our study suggests that patients with metastatic MM who express NY-ESO-1 may benefit from NY-ESO-1-based immunotherapy...
  36. ncbi Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6)
    Hearn J Cho
    Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Immun 6:12. 2006
    ..This is the first report of direct interaction between two CT antigens and may be pertinent in the light of the frequently coordinated expression of these proteins...
  37. pmc Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    Eiichi Sato
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:18538-43. 2005
    ..We conclude that intraepithelial CD8+ TILs and a high CD8+/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer...
  38. doi Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, Ltd, New York Branch, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 186:1218-27. 2011
    ..Receptor-specific delivery of NY-ESO-1 to APC appears to be a promising vaccination strategy to efficiently generate integrated and broad Ag-specific immune responses against NY-ESO-1 in cancer patients...
  39. doi Autoantibodies against cancer antigens
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 520:11-9. 2009
    ..We describe in this chapter a simple implementation of a serological monitoring platform for autoantibody measurement in cancer patients, from production of recombinant antigens to ELISA testing and interpretation...
  40. pmc Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Cancer Immun 10:1. 2010
    ..The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters...
  41. pmc Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients
    Shigehisa Kitano
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Cancer Center, New York, NY 10065
    Cancer Immunol Res 1:235-44. 2013
    ..Ipilimumab may induce the expression of lytic granules on antigen specific cytotoxic CD4(+) T cells via Eomes, revealing a novel consequence of immunologic checkpoint blockade. ..
  42. pmc Ipilimumab for patients with advanced mucosal melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 18:726-32. 2013
    ..Durable responses to ipilimumab were observed, but the overall response rate was low. Additional investigation is necessary to clarify the role of ipilimumab in patients with mucosal melanoma. ..
  43. pmc A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Departments of Medicine, Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, 1 Gustave L Levy Place, P O Box 1208, New York, NY 10029 6574, USA
    Sarcoma 2013:168145. 2013
    ..Assessment of the ability of synovial sarcoma cell lines to present cancer-germ cell antigens may be useful in determining the reason for the observed lack of immunological or clinical activity...
  44. pmc The abscopal effect associated with a systemic anti-melanoma immune response
    Emily F Stamell
    Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
    Int J Radiat Oncol Biol Phys 85:293-5. 2013
    ..This case supports the immune hypothesis for the abscopal effect, and illustrates the potential of combining radiotherapy and immunotherapy in the treatment of melanoma...
  45. pmc Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer
    Kunle Odunsi
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, 14263 Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, 14263 Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, 14263
    Cancer Immunol Res 2:37-49. 2014
    ..Based on these encouraging results, evaluation of similar combinatorial chemo-immunotherapy regimens in EOC and other tumor types is warranted. ..
  46. pmc Toll-like receptor agonists: are they good adjuvants?
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York City, NY, USA
    Cancer J 16:382-91. 2010
    ..This review summarizes the application of these adjuvants to treat cancer and the potential for boosting responses in vivo...
  47. doi Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity
    Julia Karbach
    Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany
    Clin Cancer Res 18:5449-59. 2012
    ..We developed a new, biochemically well defined and current good manufacturing practice-compliant MBV preparation, which has been investigated in patients with NY-ESO-1 expressing cancers...
  48. doi Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer
    Shinichi Fujiwara
    Department of Gastroenterological Surgery, Osaka University, Osaka, Japan
    J Immunother 35:513-21. 2012
    ....
  49. ncbi Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma
    Eleanor M Tyler
    Authors Affiliations Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences Sloan Kettering Institute Department of Pathology, Bone Marrow Transplant Service, Department of Pediatrics, and Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center The Tisch Cancer Institute, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai and Weill Medical College of Cornell University, New York, New YorkAuthors Affiliations Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences Sloan Kettering Institute Department of Pathology, Bone Marrow Transplant Service, Department of Pediatrics, and Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center The Tisch Cancer Institute, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai and Weill Medical College of Cornell University, New York, New York
    Cancer Immunol Res 2:547-58. 2014
    ..Together, these findings support the development of immunotherapeutic strategies that aim to enhance CT7-directed immune responses for the treatment of multiple myeloma...
  50. ncbi Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies
    Julia Karbach
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Res 72:4304-10. 2012
    ..Our data therefore substantiate the potency of CpG 7909 to directly stimulate human B-cells and suggest that anti-CpG antibody monitoring should be a part of ongoing and planned clinical trials with CpG-ODNs...
  51. ncbi NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 63:6076-83. 2003
    ..These findings indicate that NY-ESO-1 and LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC...
  52. ncbi Urine antibody against human cancer antigen NY-ESO-1
    Dirk Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 2:10. 2002
    ..Urine antibody detection may also be of value in the monitoring of spontaneous and vaccine-induced immunity against other defined tumor antigens...
  53. ncbi Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011
    Julia Karbach
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Int J Cancer 118:668-74. 2006
    ..The characterization of the new HLA-DQ B1 03011-restricted NY-ESO-1 peptides broadens the repertoire of epitopes that can be used to monitor NY-ESO-1-specific spontaneous and vaccine-induced T-cell responses in cancer patients...
  54. ncbi HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones
    Eduardo Huarte
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 4:15. 2004
    ..The Th1 phenotype and effector functions of the CD4+ T cell clones described here provide an important rationale for the activation of antigen-specific CD4+ T cells along with CD8+ T cells in cancer vaccination strategies...
  55. ncbi Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer
    Feng Qian
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Immun 4:12. 2004
    ..Our study supports the relevance of cancer vaccine trials with the NY-ESO-1 epitope 157-170 in HLA-DP4+ EOC patients with NY-ESO-1-expressing tumors and strategies to improve Th1-dominated tumor-reactive CD4+ T cell bias...
  56. ncbi Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer
    Yu Wang
    Typing and Monitoring Laboratory, Beijing Cancer Hospital, Beijing 100036, China
    Cancer Immun 4:11. 2004
    ..About 74% of the samples expressed at least one CT antigen, most frequently MAGE-3 (41.6%). NY-ESO-1 and MAGE-3 are thus potential targets for a multivalent CT antigen vaccine...
  57. ncbi The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
    Xiao Ying Shang
    Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People s Republic of China
    Clin Cancer Res 10:6946-55. 2004
    ....
  58. ncbi NY-ESO-1 expression and immunogenicity in esophageal cancer
    Shoichiro Fujita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
    Clin Cancer Res 10:6551-8. 2004
    ..We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients...
  59. ncbi Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments
    Gerhard Held
    Clinic for Internal Medicine I, Saarland University Medical School, Homburg Saar, Germany
    Eur J Immunol 34:2919-29. 2004
    ..It may therefore become a useful monitoring tool for the development of NY-ESO-1-based cancer vaccines...
  60. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  61. ncbi NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
    Yurika Sugita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita City, Osaka 565 0871, Japan
    Cancer Res 64:2199-204. 2004
    ....
  62. ncbi NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer
    Tetsuya Nakada
    Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Japan
    Cancer Immun 3:10. 2003
    ..CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies...
  63. ncbi Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51
    Elke Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 2:12. 2002
    ....
  64. ncbi In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope
    Kosei Hasegawa
    Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Clin Cancer Res 12:1921-7. 2006
    ....
  65. pmc Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
    Naomi N Hunder
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 358:2698-703. 2008
    ..We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1...
  66. pmc LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer
    Armin Bender
    Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 7:16. 2007
    ..A specific immune response of high magnitude and early onset may be more effective in eliminating minimal residual disease in adjuvant treatment situations and in preventing tumor progression due to immune escape mechanisms...
  67. pmc Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
    Djordje Atanackovic
    Department of Oncology Hematology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Proc Natl Acad Sci U S A 105:1650-5. 2008
    ..These data provide an immunological rationale for vaccine design in light of recently reported favorable clinical responses in NSCLC patients after vaccination with MAGE-A3 protein plus adjuvant AS02B...
  68. pmc Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
    Kunle Odunsi
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Proc Natl Acad Sci U S A 104:12837-42. 2007
    ....
  69. ncbi Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination
    Julia Karbach
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Int J Cancer 121:2042-8. 2007
    ....
  70. doi Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1
    Junko Matsuzaki
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 57:1185-95. 2008
    ..Together, the results indicate that ESO119-143 epitope has dual HLA classes I and II specificities, and represents a potential vaccine candidate in a large number of cancer patients...
  71. ncbi Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
    Djordje Atanackovic
    Department of Oncology Hematology, Institute for Biochemistry and Molecular Biology, University Medical Center Hamburg Eppendorf, Germany
    Blood 109:1103-12. 2007
    ..Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM...
  72. pmc Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
    Elke Jager
    Ludwig Institute Clinical Trial Center, Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, Steinbacher Hohl 2 26, 60488 Frankfurt, Germany
    Proc Natl Acad Sci U S A 103:14453-8. 2006
    ..In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination...
  73. ncbi Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Immunother 30:847-54. 2007
    ..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM...
  74. pmc Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008
    ..These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels...
  75. ncbi RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
    Michael Schmitt
    Department of Internal Medicine III, University of Ulm, Ulm, Germany
    Blood 111:1357-65. 2008
    ..This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37...
  76. ncbi Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content
    Sheng Wei Ye
    Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital, No 52 Fu cheng Road, Hai Dian District, Beijing 100036, PR China
    J Clin Immunol 26:447-56. 2006
    ....
  77. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
    ..001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC...
  78. ncbi Immunogenic targets in non-small cell lung cancer: more is more
    Sacha Gnjatic
    Clin Cancer Res 11:5331-2. 2005
  79. doi Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling
    Hiroyoshi Nishikawa
    Department of Cancer Vaccine, Mie University Graduate School of Medicine, Mie, Japan
    Cancer Res 68:5948-54. 2008
    ..We propose that coadministration of GITR signaling agents with tumor antigens constitutes a promising novel strategy for cancer vaccine development...